Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 1996;7:133–41.
Article
PubMed
CAS
Google Scholar
Mayo C, Bertran-Alamillo J, Molina-Vila MÁ, Giménez-Capitán A, Costa C, Rosell R. Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics. 2012;13:789–802.
Article
PubMed
CAS
Google Scholar
Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol. 2003;30:25–33.
Article
PubMed
CAS
Google Scholar
Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol. 2004;22:3080–90.
Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012;30:4017–25.
Terada T, Noda S, Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125–34.
Article
PubMed
CAS
Google Scholar
Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MAJ, Beijnen JH, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008;7:2280–7.
Article
PubMed
CAS
Google Scholar
Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13:3731–7.
Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin J-E, Riek M, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol. 2008;64:31–41.
Article
PubMed
CAS
Google Scholar
Hamilton M, Wolf JL, Drolet DW, Fettner SH, Rakhit AK, Witt K, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol. 2014;73:613–21.
Article
PubMed
CAS
Google Scholar
Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36.
Article
PubMed
CAS
Google Scholar
Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res. 2011;17:89–99.
Tournier N, Goutal S, Auvity S, Traxl A, Mairinger S, Wanek T, et al. Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study on nonhuman primates. J Nucl Med. 2017;58:117–22.
Traxl A, Wanek T, Mairinger S, Stanek J, Filip T, Sauberer M, et al. Breast cancer resistance protein and P-glycoprotein influence in vivo disposition of 11C-erlotinib. J Nucl Med. 2015;56:1930–6.
Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, et al. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Clin Pharmacol Ther. 2018;104:139-147.
Giacomini KM, Huang S-M. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94:3–9.
Article
PubMed
CAS
Google Scholar
Hagenbuch B, Stieger B. The SLCO (former SLC21) superfamily of transporters. Mol Asp Med. 2013;34:396–412.
Article
CAS
Google Scholar
Bahce I, Smit EF, Lubberink M, van der Veldt AAM, Yaqub M, Windhorst AD, et al. Development of [(11)C] erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:183–93.
Article
CAS
Google Scholar
Neyt S, Huisman MT, Vanhove C, De Man H, Vliegen M, Moerman L, et al. In vivo visualization and quantification of (disturbed) Oatp-mediated hepatic uptake and Mrp2-mediated biliary excretion of 99mTcmebrofenin in mice. J Nucl Med. 2013;54:624–30.
He J, Yu Y, Prasad B, Link J, Miyaoka RS, Chen X, et al. PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat. Mol Pharm. 2014;11:2745–54.
Article
PubMed
CAS
Google Scholar
Takashima T, Hashizume Y, Katayama Y, Murai M, Wada Y, Maeda K, et al. The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [11C]telmisartan. Mol Pharm. 2011;8:1789–98.
Article
PubMed
CAS
Google Scholar
Shingaki T, Takashima T, Ijuin R, Zhang X, Onoue T, Katayama Y, et al. Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C] dehydropravastatin in rats. J Pharmacol Exp Ther. 2013;347:193–202.
Article
PubMed
CAS
Google Scholar
Marie S, Cisternino S, Buvat I, Declèves X, Tournier N. Imaging probes and modalities for the study of solute carrier O (SLCO)-transport function in vivo. J Pharm Sci. 2017;106:2335–44.
Article
PubMed
CAS
Google Scholar
Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, et al. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 2013;94:23–6.
Article
PubMed
CAS
Google Scholar
König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65:944–66.
Article
PubMed
CAS
Google Scholar
Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85:78–85.
Article
PubMed
CAS
Google Scholar
Parvez MM, Jung JA, Shin HJ, Kim DH, Shin J-G. Characterization of 22 antituberculosis drugs for inhibitory interaction potential on organic anionic transporter polypeptide (OATP)-mediated uptake. Antimicrob Agents Chemother. 2016;60:3096–105.
Article
PubMed
PubMed Central
CAS
Google Scholar
Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012;55:4740–63.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatol Baltim Md. 2000;32:82–6.
Article
CAS
Google Scholar
Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006;34:1175–81.
Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, et al. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002;19:147–53.
Article
PubMed
CAS
Google Scholar
Parvez MM, Kaisar N, Shin HJ, Jung JA, Shin J-G. Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A family. Antimicrob Agents Chemother. 2016;60:6558–67.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006;34:420–6.
Sato T, Mishima E, Mano N, Abe T, Yamaguchi H. Potential drug interactions mediated by renal organic anion transporter OATP4C1. J Pharmacol Exp Ther. 2017;362:271–7.
Article
PubMed
CAS
Google Scholar
Traxl A, Komposch K, Glitzner E, Wanek T, Mairinger S, Langer O, et al. Hepatocyte-specific deletion of EGFR in mice reduces hepatic Abcg2 transport activity measured by [(11)C] erlotinib and positron emission tomography. Drug Metab Dispos Biol Fate Chem. 2017;45:1093–100.
Article
PubMed
CAS
Google Scholar
Abbiati RA, Manca D. Enterohepatic circulation effect in physiologically based pharmacokinetic models: the sorafenib case. Ind Eng Chem Res. 2017;56:3156–66.
Article
CAS
Google Scholar
Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, et al. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001;443:188–95.
Article
PubMed
CAS
Google Scholar
Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260–87.
Article
PubMed
PubMed Central
CAS
Google Scholar
Takashima T, Kitamura S, Wada Y, Tanaka M, Shigihara Y, Ishii H, et al. PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. J Nucl Med. 2012;53:741–8.
Neul C, Schaeffeler E, Sparreboom A, Laufer S, Schwab M, Nies AT. Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors. Trends Pharmacol Sci. 2016;37:904–32.
Article
PubMed
CAS
Google Scholar
Mann A, Semenenko I, Meir M, Eyal S. Molecular imaging of membrane transporters’ activity in cancer: a picture is worth a thousand tubes. AAPS J. 2015;17:788–801.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tournier N, Stieger B, Langer O. Imaging techniques to study drug transporter function in vivo. Pharmacol Ther. doi: https://doi.org/10.1016/j.pharmthera.2018.04.006. [Epub ahead of print].